Search
Now showing items 1-5 of 5
Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update.
(Sociedad Argentina de Pediatría., 2017-06-01)
Lysosomal acid lipase deficiency (LAL-D) is still a little recognized genetic disease with significant morbidity and mortality in children and adults. This document provides guidance on when to suspect LAL-D and how to ...
Involvement of hepatic macrophages in the antifibrotic effect of IGF-I_overexpressing mesenchymal stromal cells.
(BMC (part of Springer Nature), 2016-11-22)
BACKGROUND:
Cirrhosis is a major health problem worldwide and new therapies are needed. Hepatic macrophages (hMø) have a pivotal role in liver fibrosis, being able to act in both its promotion and its resolution. It is ...
A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management
(Elsevier, 2020-07)
Abstract
Introduction & objectives: Liver cirrhosis is a major cause of mortality worldwide. Adequate diagnosis and treatment of decompensating events requires of both medical skills and updated technical resources. The ...
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
(Elsevier, 2020-11)
Abstract
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its ...
The liver in times of COVID-19: What hepatologists should know
(Elsevier, 2020-07)
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding how the infection affects the liver and relevance of pre-existing ...